Results 21 to 30 of about 24,893 (251)

Atypical Hemolytic-Uremic Syndrome: Genetic Basis, Clinical Manifestations, and a Multidisciplinary Approach to Management

Journal of Multidisciplinary Healthcare, 2023
Hemolytic uremic syndrome (HUS) is a thrombotic microangiopathy (TMA) defined by the triad of hemolytic anemia, thrombocytopenia, and acute kidney injury.
Keval Yerigeri, S. Kadatane, Kai Mongan, O. Boyer, Linda Burke, S. Sethi, Christoph Licht, R. Raina   +7 more
semanticscholar   +1 more source

CFH and CFHR structural variants in atypical Hemolytic Uremic Syndrome: Prevalence, genomic characterization and impact on outcome

Frontiers in Immunology, 2023
Introduction Atypical hemolytic uremic syndrome (aHUS) is a rare disease that manifests with microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure, and is associated with dysregulation of the alternative complement pathway.
R. Piras, E. Valoti, M. Alberti, E. Bresin, C. Mele, M. Breno, L. Liguori, R. Donadelli, M. Rigoldi, A. Benigni, G. Remuzzi, M. Noris   +11 more
semanticscholar   +1 more source

Pharmacological Management of Atypical Hemolytic Uremic Syndrome in Pediatric Patients: Current and Future

Pediatric Drugs, 2023
Atypical hemolytic uremic syndrome is a thrombotic microangiopathy characterized by hemolysis, thrombocytopenia, and acute kidney injury, usually caused by alternative complement system overactivation due to pathogenic genetic variants or antibodies to ...
Evgenia Gurevich, D. Landau
semanticscholar   +1 more source

Design and Rationale of the APPELHUS Phase 3 Open-Label Study of Factor B Inhibitor Iptacopan for Atypical Hemolytic Uremic Syndrome

Kidney International Reports, 2023
Introduction Atypical hemolytic uremic syndrome (aHUS) is a rare, progressive, and life-threatening form of thrombotic microangiopathy (TMA) which is caused by dysregulation of the alternative complement pathway (AP).
D. Kavanagh, L. Greenbaum, A. Bagga, R. Karki, Chien-Wei Chen, Sajita Vasudevan, A. Charney, M. Dahlke, F. Fakhouri   +8 more
semanticscholar   +1 more source

Recommendations for the individualised management of atypical hemolytic uremic syndrome in adults

Frontiers in Medicine, 2023
Background Despite significant advances in therapeutic management of atypical hemolytic uremic syndrome (aHUS), guidelines are not timely updated and achieving a consensus on management recommendations remains a topic of ongoing discussion.
Ana Ávila, M. Cao, Mario Espinosa, J. Manrique, E. Morales   +4 more
semanticscholar   +1 more source

Treatment preference and quality of life impact: ravulizumab vs eculizumab for atypical hemolytic uremic syndrome

Journal of Comparative Effectiveness Research, 2023
Aim: Ravulizumab and eculizumab are complement C5 inhibitors approved for the treatment of atypical hemolytic uremic syndrome (aHUS). Ravulizumab requires less frequent infusions than eculizumab, which may reduce treatment burden. This study investigated
Teri J Mauch, Michael R. Chladek, S. Cataland, Shruti Chaturvedi, B. Dixon, Katherine Garlo, C. Gasteyger, A. Java, Jorge P. Leguizamo, L. Lloyd-Price, T. Pham, T. Symonds, I. Tomazos, Yan Wang   +13 more
semanticscholar   +1 more source

Hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli in a renal transplant recipient case report

Brazilian Journal of Nephrology, 2020
Thrombotic microangiopathies are disorders characterized by nonimmune microangiopathic hemolytic anemia, thrombocytopenia, and multi-systemic failure.
John Fredy Nieto-Rios, Monica Zuluaga-Quintero, Julio Cesar Valencia-Maturana, Diana Carolina Bello-Marquez, Arbey Aristizabal-Alzate, Gustavo Adolfo Zuluaga-Valencia, Lina Maria Serna-Higuita, Luis Fernando Arias   +7 more
doaj   +2 more sources

Transplantation in Atypical Hemolytic Uremic Syndrome [PDF]

Seminars in Thrombosis and Hemostasis, 2010
Atypical hemolytic uremic syndrome (aHUS) is a disease characterized by overactivation of complement. Recurrence following renal transplantation is determined by a genetic predisposition. Genetic screening of all individuals with aHUS should be performed prior to listing for transplantation. Individuals with isolated mutations in MCP have a low risk of
Kavanagh D, Richards A, Goodship T, Jalanko H   +3 more
openaire   +3 more sources

Eculizumab Rescue Therapy in Patients With Recurrent Atypical Hemolytic Uremic Syndrome After Kidney Transplantation.

Kidney International Reports, 2023
Introduction Since 2016, kidney transplantation in patients with atypical hemolytic uremic syndrome (aHUS) in the Netherlands is performed without eculizumab prophylaxis. Eculizumab is given in case of posttransplant aHUS recurrence.
Caroline Duineveld, R. Bouwmeester, K. Wijnsma, F. J. Bemelman, J. W. van der Heijden, S. Berger, L. P. van den Heuvel, N. C. van de Kar, J. Wetzels   +8 more
semanticscholar   +1 more source

Pregnancy-Induced Atypical Hemolytic Uremic Syndrome. [PDF]

Cureus
Atypical hemolytic uremic syndrome (aHUS) is a rare form of thrombotic microangiopathy that causes anemia, thrombocytopenia, and acute renal failure. In aHUS, a triggering event can lead to dysregulation of the complement immune system, leading to a cascade of events resulting in clot formation, capillary thrombosis, and renal dysfunction.
Den Boef A, Parekh S, O'Brien MC, Liu S, Jacob R.   +4 more
europepmc   +3 more sources